Overview
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Status:
Recruiting
Recruiting
Trial end date:
2023-08-01
2023-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mirati Therapeutics Inc.Treatments:
Adagrasib
Docetaxel
Criteria
Inclusion Criteria:- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
Exclusion Criteria:
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510).
- Active brain metastases.